{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.2","upperLimit":"93.5","value":"76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate the 6 month PFS. PFS is defined as time from initiation of protocol treatment to disease progression, recurrence, death from any cause, or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive larotrectinib sulfate PO or via NG- or G-tube BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, an x-ray, bone scan, and/or MIBG scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.","id":"OG000","title":"Treatment (Larotrectinib Sulfate)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 months from study entry","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}